CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work and can afford the risks. Trading CFDs is high risk and is not suitable for everyone. Refer to our PDS and Target Market Determination. AFSL 513393
Open platformOpen platform

UK's Inspiration Healthcare H1 underlying revenue rises on neonatal ventilation segment

By Reuters News


Overview

  • UK neonatal device maker's H1 revenue fell due to prior year one-off export orders

  • Underlying H1 revenue rose 26% excluding last year's one-off export orders

  • Adjusted EBITDA was stable, while operating profit rose on non-recurring credit


Outlook

  • Company expects FY27 revenue of at least £43 mln

  • Company expects positive momentum to continue into FY28

  • Planned launch of proprietary consumables in Q4 FY27 expected to support future growth


Result Drivers

  • NEONATAL VENTILATION - Co said strong momentum in neonatal ventilation portfolio drove underlying growth

  • SLE SALES - SLE product sales rose, with notable gains in capital equipment and service revenues

  • INFUSION THERAPIES RECOVERY - Co said recovery in Infusion Therapies sales contributed to distribution revenue growth


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

H1 Adjusted EBITDA

GBP 1.20 mln

H1 Gross Margin

41.90%

H1 EBIT

GBP 550,000


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

  • Wall Street's median 12-month price target for Inspiration Healthcare Group PLC is GBp34.00, about 83.8% above its October 26 closing price of GBp18.50


Reuters Recommended Reads

  • Oct 26 - UK's Computacenter raises profit forecast for fourth time this year, shares rise

  • Oct 26 - Senior doctors in England set to strike over pay offer in November

  • Oct 26 - GSK, Hansoh's bone cancer drug delays disease progression in late-stage China study


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.